Erik Roelofs

Erik Roelofs

Auto-generated profile, based on publicly available information

Erik Roelofs

Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Centre , Maastricht

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2012 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
PLPhilippe Lambin
Philippe Lambin
RSRuud G. P. M. van Stiphout
Ruud G. P. M. van Stiphout
MSMaud H. W. Starmans
Maud H. W. Starmans
EREmmanuel Rios-Velazquez
Emmanuel Rios-Velazquez
GNGeorgi Nalbantov
Georgi Nalbantov
ADAndré Dekker
André Dekker

1 October 2013 in Radiotherapy and Oncology
Verified
Journal Article
Open access
PLPhilippe Lambin
Philippe Lambin
ERErik Roelofs
Erik Roelofs
BRBart Reymen
Bart Reymen
EVEmmanuel Rios Velazquez
Emmanuel Rios Velazquez
JBJeroen Buijsen
Jeroen Buijsen
ADAndré Dekker
André Dekker
An overview of the Rapid Learning methodology, its results, and the potential impact on radiotherapy. Rapid Learning methodology is divided into four phases. In the data phase, diverse data are collected about past patients, treatments used, and outcomes. Innovative information technologies that support semantic interoperability enable distributed learning and data sharing without additional burden on health care professionals and without the need for data to leave the hospital. In the knowledge phase, prediction models are developed for new data and treatment outcomes by applying machine learning methods to data. In the application phase, this knowledge is applied in clinical practice via novel decision support systems or via extensions of existing models such as Tumour Control Probability models. In the evaluation phase, the predictability of treatment outcomes allows the new knowledge to be evaluated by comparing predicted and actual outcomes. Personalised or tailored cancer therapy ensures not only that patients receive an optimal treatment, but also that the right resources are being used for the right patients. Rapid Learning approaches combined with evidence based medicine are expected to improve the predictability of outcome and radiotherapy is the ideal field to study the value of Rapid Learning. The next step will be to include patient preferences in the decision making.

1 January 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
PLPhilippe Lambin
Philippe Lambin
JZJaap Zindler
Jaap Zindler
BVBen G.L. Vanneste
Ben G.L. Vanneste
LVLien Van De Voorde
Lien Van De Voorde
DEDaniëlle Eekers
Daniëlle Eekers
SWSean Walsh
Sean Walsh

1 January 2012 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
ERErik Roelofs
Erik Roelofs
MEMartijn Engelsman
Martijn Engelsman
CRCoen Rasch
Coen Rasch
LPLucas Persoon
Lucas Persoon
SQSima Qamhiyeh
Sima Qamhiyeh
Philippe LambinPhilippe Lambin
Philippe Lambin

21 September 2015 in Acta Oncologica
Verified
Journal Article
Closed access
PDF file
PLPhilippe Lambin
Philippe Lambin
JZJaap Zindler
Jaap Zindler
BVBen Vanneste
Ben Vanneste
LVLien van de Voorde
Lien van de Voorde
MJMaria Jacobs
Maria Jacobs
SWSean Walsh
Sean Walsh
Background. Trials are vital in informing routine clinical care; however, current designs have major deficiencies. An overview of the various challenges that face modern clinical research and the methods that can be exploited to solve these challenges, in the context of personalised cancer treatment in the 21st century is provided. Aim. The purpose of this manuscript, without intending to be comprehensive, is to spark thought whilst presenting and discussing two important and complementary alternatives to traditional evidence-based medicine, specifically rapid learning health care and cohort multiple randomised controlled trial design. Rapid learning health care is an approach that proposes to extract and apply knowledge from routine clinical care data rather than exclusively depending on clinical trial evidence, (please watch the animation: http://youtu.be/ZDJFOxpwqEA). The cohort multiple randomised controlled trial design is a pragmatic method which has been proposed to help overcome the weaknesses of conventional randomised trials, taking advantage of the standardised follow-up approaches more and more used in routine patient care. This approach is particularly useful when the new intervention is a priori attractive for the patient (i.e. proton therapy, patient decision aids or expensive medications), when the outcomes are easily collected, and when there is no need of a placebo arm. Discussion. Truly personalised cancer treatment is the goal in modern radiotherapy. However, personalised cancer treatment is also an immense challenge. The vast variety of both cancer patients and treatment options makes it extremely difficult to determine which decisions are optimal for the individual patient. Nevertheless, rapid learning health care and cohort multiple randomised controlled trial design are two approaches (among others) that can help meet this challenge.

1 February 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ERErik Roelofs
Erik Roelofs
ADAndré Dekker
André Dekker
EMElisa Meldolesi
Elisa Meldolesi
RSRuud G.P.M. van Stiphout
Ruud G.P.M. van Stiphout
VVVincenzo Valentini
Vincenzo Valentini
Philippe LambinPhilippe Lambin
Philippe Lambin